Skip to main content
Erschienen in: European Radiology 10/2023

01.08.2023 | Review

The effect of CALIPER-derived parameters for idiopathic pulmonary fibrosis in predicting prognosis, progression, and mortality: a systematic review

verfasst von: Xin-yao Jiao, Han Song, Wei-wu Liu, Jun-ling Yang, Zhi-wei Wang, Dan Yang, Sa Huang

Erschienen in: European Radiology | Ausgabe 10/2023

Einloggen, um Zugang zu erhalten

Abstract

Background

High-resolution computed tomography (HRCT), as the main tool for monitoring idiopathic pulmonary fibrosis (IPF), is characterized by subjective variability among radiologists and insensitivity to subtle changes. Recently, a few studies have aimed to decrease subjective bias by assessing the severity of IPF using computer software, i.e., Computer-Aided Lung Informatics for Pathology Evaluation and Rating (CALIPER). However, these studies had diverse research directions. In this review, we systematically assess the effect of CALIPER in the management of IPF.

Methods

A systematic review was conducted through a search of published studies in PubMed, Web of Science, Cochrane, Embase, Scopus, and CNKI databases from database inception through February 28, 2022. The methodological quality would be evaluated by using Methodological Index for Non-Randomized Studies (MINORS). Narrative synthesis summarized findings by participant characteristics, study design, and associations with outcomes.

Results

Ten studies were included. They evaluated the relationship between CALIPER-derived parameters and pulmonary function test (PFT) and mortality. CALIPER-derived parameters showed a significant correlation with PFT and mortality. Two studies reported that CALIPER could be used to stratify outcomes.

Conclusion

CALIPER-derived parameters can be used to evaluate prognosis and mortality. CALIPER-derived parameters combined with composite physiologic index (CPI) or Gender-Age-Physiology (GAP) could help clinicians implement targeted management by refining prognostic stratification. However, research has been constrained by small number of retrospective investigations and sample sizes. Therefore, it is essential to design prospective controlled studies and establish the staging system by CALIPER-derived parameters and combining them with CPI, FVC, or GAP.

Clinical relevance statement

It is beneficial for clinic to provide objective, sensitive, and accurate indicators of disease progression. It also helps the clinic to develop individualized treatment plans based on the stage of disease progression and provides evaluation of efficacy in drug trials.

Key Points

• Computer-Aided Lung Informatics for Pathology Evaluation and Rating (CALIPER) is a quantitative CT analysis software that can be used to evaluate the progression of disease on CT.
• The CALIPER-derived vessel-related structure shows great performance in the management of idiopathic pulmonary fibrosis.
• CALIPER-derived parameters combined with composite physiologic index or Gender-Age-Physiology can be used to refine prognostic stratification.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Flaherty KR, Kolb M, Vancheri C, Tang W, Conoscenti CS, Richeldi L (2018) Stability or improvement in forced vital capacity with nintedanib in patients with idiopathic pulmonary fibrosis. Eur Respir J 52(2):1702593PubMed Flaherty KR, Kolb M, Vancheri C, Tang W, Conoscenti CS, Richeldi L (2018) Stability or improvement in forced vital capacity with nintedanib in patients with idiopathic pulmonary fibrosis. Eur Respir J 52(2):1702593PubMed
2.
Zurück zum Zitat Nalysnyk L, Cid-Ruzafa J, Rotella P, Esser D (2012) Incidence and prevalence of idiopathic pulmonary fibrosis: review of the literature. Eur Respir Rev 21:355–361PubMedPubMedCentral Nalysnyk L, Cid-Ruzafa J, Rotella P, Esser D (2012) Incidence and prevalence of idiopathic pulmonary fibrosis: review of the literature. Eur Respir Rev 21:355–361PubMedPubMedCentral
3.
Zurück zum Zitat Raghu G, Remy-Jardin M, Richeldi L et al (2022) Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults: an Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. Am J Respir Crit Care Med 205:e18–e47PubMedPubMedCentral Raghu G, Remy-Jardin M, Richeldi L et al (2022) Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults: an Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. Am J Respir Crit Care Med 205:e18–e47PubMedPubMedCentral
4.
Zurück zum Zitat Hutchinson J, Fogarty A, Hubbard R, McKeever T (2015) Global incidence and mortality of idiopathic pulmonary fibrosis: a systematic review. Eur Respir J 46:795–806PubMed Hutchinson J, Fogarty A, Hubbard R, McKeever T (2015) Global incidence and mortality of idiopathic pulmonary fibrosis: a systematic review. Eur Respir J 46:795–806PubMed
5.
Zurück zum Zitat Rivera-Ortega P, Molina-Molina M (2019) Interstitial lung diseases in developing countries. Ann Global Health 85(1):4 Rivera-Ortega P, Molina-Molina M (2019) Interstitial lung diseases in developing countries. Ann Global Health 85(1):4
6.
Zurück zum Zitat Wakwaya Y, Brown KK (2019) Idiopathic pulmonary fibrosis: epidemiology, diagnosis and outcomes. Am J Med Sci 357:359–369PubMed Wakwaya Y, Brown KK (2019) Idiopathic pulmonary fibrosis: epidemiology, diagnosis and outcomes. Am J Med Sci 357:359–369PubMed
7.
Zurück zum Zitat Salciccioli JD, Marshall DC, Goodall R et al (2022) Interstitial lung disease incidence and mortality in the UK and the European Union: an observational study, 2001–2017. ERJ Open Res 8(3):00058-2022 Salciccioli JD, Marshall DC, Goodall R et al (2022) Interstitial lung disease incidence and mortality in the UK and the European Union: an observational study, 2001–2017. ERJ Open Res 8(3):00058-2022
8.
Zurück zum Zitat Costabel U, Inoue Y, Richeldi L et al (2016) Efficacy of nintedanib in idiopathic pulmonary fibrosis across prespecified subgroups in INPULSIS. Am J Respir Crit Care Med 193:178–185PubMed Costabel U, Inoue Y, Richeldi L et al (2016) Efficacy of nintedanib in idiopathic pulmonary fibrosis across prespecified subgroups in INPULSIS. Am J Respir Crit Care Med 193:178–185PubMed
9.
Zurück zum Zitat Martusewicz-Boros M, Gorska K (2020) Nintedanib - efficacy, safety and practical aspects of treatment for patients with idiopathic pulmonary fibrosis. Adv Respir Med 88:599–607PubMed Martusewicz-Boros M, Gorska K (2020) Nintedanib - efficacy, safety and practical aspects of treatment for patients with idiopathic pulmonary fibrosis. Adv Respir Med 88:599–607PubMed
10.
Zurück zum Zitat Aono Y, Nakamura Y, Kono M et al (2020) Prognostic significance of forced vital capacity decline prior to and following antifibrotic therapy in idiopathic pulmonary fibrosis. Ther Adv Respir Dis 14:1753466620953783. Aono Y, Nakamura Y, Kono M et al (2020) Prognostic significance of forced vital capacity decline prior to and following antifibrotic therapy in idiopathic pulmonary fibrosis. Ther Adv Respir Dis 14:1753466620953783.
11.
Zurück zum Zitat Durheim MT, Bendstrup E, Carlson L et al (2021) Outcomes of patients with advanced idiopathic pulmonary fibrosis treated with nintedanib or pirfenidone in a real-world multicentre cohort. Respirology 26:982–988PubMed Durheim MT, Bendstrup E, Carlson L et al (2021) Outcomes of patients with advanced idiopathic pulmonary fibrosis treated with nintedanib or pirfenidone in a real-world multicentre cohort. Respirology 26:982–988PubMed
12.
Zurück zum Zitat Mooney J, Reddy SR, Chang E, Broder MS, Gokhale S, Corral M (2021) Antifibrotic therapies reduce mortality and hospitalization among Medicare beneficiaries with idiopathic pulmonary fibrosis. J Manag Care Spec Pharm 27:1724–1733PubMed Mooney J, Reddy SR, Chang E, Broder MS, Gokhale S, Corral M (2021) Antifibrotic therapies reduce mortality and hospitalization among Medicare beneficiaries with idiopathic pulmonary fibrosis. J Manag Care Spec Pharm 27:1724–1733PubMed
13.
Zurück zum Zitat Raghu G, Collard HR, Egan JJ et al (2011) An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 183:788–824PubMedPubMedCentral Raghu G, Collard HR, Egan JJ et al (2011) An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 183:788–824PubMedPubMedCentral
14.
Zurück zum Zitat Paterniti MO, Bi Y, Rekic D, Wang Y, Karimi-Shah BA, Chowdhury BA (2017) Acute exacerbation and decline in forced vital capacity are associated with increased mortality in idiopathic pulmonary fibrosis. Ann Am Thorac Soc 14:1395–1402PubMed Paterniti MO, Bi Y, Rekic D, Wang Y, Karimi-Shah BA, Chowdhury BA (2017) Acute exacerbation and decline in forced vital capacity are associated with increased mortality in idiopathic pulmonary fibrosis. Ann Am Thorac Soc 14:1395–1402PubMed
15.
Zurück zum Zitat Durheim MT, Collard HR, Roberts RS et al (2015) Association of hospital admission and forced vital capacity endpoints with survival in patients with idiopathic pulmonary fibrosis: analysis of a pooled cohort from three clinical trials. Lancet Respir Med 3:388–396PubMedPubMedCentral Durheim MT, Collard HR, Roberts RS et al (2015) Association of hospital admission and forced vital capacity endpoints with survival in patients with idiopathic pulmonary fibrosis: analysis of a pooled cohort from three clinical trials. Lancet Respir Med 3:388–396PubMedPubMedCentral
16.
Zurück zum Zitat Zurkova M, Kriegova E, Kolek V et al (2019) Effect of pirfenidone on lung function decline and survival: 5-yr experience from a real-life IPF cohort from the Czech EMPIRE registry. Respir Res 20(1):16PubMedPubMedCentral Zurkova M, Kriegova E, Kolek V et al (2019) Effect of pirfenidone on lung function decline and survival: 5-yr experience from a real-life IPF cohort from the Czech EMPIRE registry. Respir Res 20(1):16PubMedPubMedCentral
17.
Zurück zum Zitat Pellegrino R, Viegi G, Brusasco V et al (2005) Interpretative strategies for lung function tests. Eur Respir J 26:948–968PubMed Pellegrino R, Viegi G, Brusasco V et al (2005) Interpretative strategies for lung function tests. Eur Respir J 26:948–968PubMed
18.
Zurück zum Zitat Cottin V, Cordier J-F (2009) The syndrome of combined pulmonary fibrosis and emphysema. Chest 136(1):1–2PubMed Cottin V, Cordier J-F (2009) The syndrome of combined pulmonary fibrosis and emphysema. Chest 136(1):1–2PubMed
20.
Zurück zum Zitat Hansell DM, Goldin JG, King TE, Lynch DA, Richeldi L, Wells AU (2015) CT staging and monitoring of fibrotic interstitial lung diseases in clinical practice and treatment trials: a Position Paper from the Fleischner Society. Lancet Respir Med 3:483–496PubMed Hansell DM, Goldin JG, King TE, Lynch DA, Richeldi L, Wells AU (2015) CT staging and monitoring of fibrotic interstitial lung diseases in clinical practice and treatment trials: a Position Paper from the Fleischner Society. Lancet Respir Med 3:483–496PubMed
21.
Zurück zum Zitat Behr J (2017) Disease progression in idiopathic pulmonary fibrosis FVC is not enough. Am J Respir Crit Care Med 196:1094–1095PubMed Behr J (2017) Disease progression in idiopathic pulmonary fibrosis FVC is not enough. Am J Respir Crit Care Med 196:1094–1095PubMed
22.
Zurück zum Zitat Yoon HY, Kim TH, Seo JB et al (2019) Effects of emphysema on physiological and prognostic characteristics of lung function in idiopathic pulmonary fibrosis. Respirology 24:55–62PubMed Yoon HY, Kim TH, Seo JB et al (2019) Effects of emphysema on physiological and prognostic characteristics of lung function in idiopathic pulmonary fibrosis. Respirology 24:55–62PubMed
23.
Zurück zum Zitat Schmidt SL, Nambiar AM, Tayob N et al (2011) Pulmonary function measures predict mortality differently in IPF versus combined pulmonary fibrosis and emphysema. Eur Respir J 38:176–183PubMed Schmidt SL, Nambiar AM, Tayob N et al (2011) Pulmonary function measures predict mortality differently in IPF versus combined pulmonary fibrosis and emphysema. Eur Respir J 38:176–183PubMed
24.
Zurück zum Zitat Watadani T, Sakai F, Johkoh T et al (2013) Interobserver variability in the CT assessment of honeycombing in the lungs. Radiology 266:936–944PubMed Watadani T, Sakai F, Johkoh T et al (2013) Interobserver variability in the CT assessment of honeycombing in the lungs. Radiology 266:936–944PubMed
25.
Zurück zum Zitat Widell J, Liden M (2020) Interobserver variability in high-resolution CT of the lungs. Eur J Radiol Open 7:100228 Widell J, Liden M (2020) Interobserver variability in high-resolution CT of the lungs. Eur J Radiol Open 7:100228
26.
Zurück zum Zitat Walsh SLF (2018) Imaging biomarkers and staging in IPF. Curr Opin Pulm Med 24:445–452PubMed Walsh SLF (2018) Imaging biomarkers and staging in IPF. Curr Opin Pulm Med 24:445–452PubMed
27.
Zurück zum Zitat Chen A, Karwoski RA, Gierada DS, Bartholmai BJ, Koo CW (2020) Quantitative CT analysis of diffuse lung disease. Radiographics 40:28–43PubMed Chen A, Karwoski RA, Gierada DS, Bartholmai BJ, Koo CW (2020) Quantitative CT analysis of diffuse lung disease. Radiographics 40:28–43PubMed
28.
Zurück zum Zitat Jankharia B, Angirish B (2021) Computer-aided quantitative analysis in interstitial lung diseases-a pictorial review using CALIPER. Lung India 38:161–167PubMedPubMedCentral Jankharia B, Angirish B (2021) Computer-aided quantitative analysis in interstitial lung diseases-a pictorial review using CALIPER. Lung India 38:161–167PubMedPubMedCentral
29.
Zurück zum Zitat Jacob J, Bartholmai BJ, Rajagopalan S et al (2018) Predicting outcomes in idiopathic pulmonary fibrosis using automated computed tomographic analysis. Am J Respir Crit Care Med 198:767–776PubMedPubMedCentral Jacob J, Bartholmai BJ, Rajagopalan S et al (2018) Predicting outcomes in idiopathic pulmonary fibrosis using automated computed tomographic analysis. Am J Respir Crit Care Med 198:767–776PubMedPubMedCentral
31.
Zurück zum Zitat Erickson BJ, Korfiatis P, Akkus Z, Kline TL (2017) Machine learning for medical imaging(1). Radiographics 37:505–515PubMed Erickson BJ, Korfiatis P, Akkus Z, Kline TL (2017) Machine learning for medical imaging(1). Radiographics 37:505–515PubMed
32.
Zurück zum Zitat Bartholmai BJ, Raghunath S, Karwoski RA et al (2013) Quantitative computed tomography imaging of interstitial lung diseases. J Thorac Imaging 28:298–307PubMed Bartholmai BJ, Raghunath S, Karwoski RA et al (2013) Quantitative computed tomography imaging of interstitial lung diseases. J Thorac Imaging 28:298–307PubMed
33.
Zurück zum Zitat Newell JD Jr, Tschirren J, Peterson S, Beinlich M, Sieren J (2019) Quantitative CT of interstitial lung disease. Semin Roentgenol 54:73–79PubMed Newell JD Jr, Tschirren J, Peterson S, Beinlich M, Sieren J (2019) Quantitative CT of interstitial lung disease. Semin Roentgenol 54:73–79PubMed
34.
Zurück zum Zitat Robbie H, Daccord C, Chua F, Devaraj A (2017) Evaluating disease severity in idiopathic pulmonary fibrosis. Eur Respir 26(145):170051 Robbie H, Daccord C, Chua F, Devaraj A (2017) Evaluating disease severity in idiopathic pulmonary fibrosis. Eur Respir 26(145):170051
36.
Zurück zum Zitat Sverzellati N, Silva M, Seletti V et al (2020) Stratification of long-term outcome in stable idiopathic pulmonary fibrosis by combining longitudinal computed tomography and forced vital capacity. Eur Radiol 30:2669–2679PubMed Sverzellati N, Silva M, Seletti V et al (2020) Stratification of long-term outcome in stable idiopathic pulmonary fibrosis by combining longitudinal computed tomography and forced vital capacity. Eur Radiol 30:2669–2679PubMed
37.
Zurück zum Zitat Romei C, Tavanti LM, Taliani A et al (2020) Automated computed tomography analysis in the assessment of idiopathic pulmonary fibrosis severity and progression. Eur J Radiol 124:108852 Romei C, Tavanti LM, Taliani A et al (2020) Automated computed tomography analysis in the assessment of idiopathic pulmonary fibrosis severity and progression. Eur J Radiol 124:108852
38.
Zurück zum Zitat Jacob J, Bartholmai BJ, Rajagopalan S et al (2016) Automated quantitative computed tomography versus visual computed tomography scoring in idiopathic pulmonary fibrosis: validation against pulmonary function. J Thorac Imaging 31:304–311PubMed Jacob J, Bartholmai BJ, Rajagopalan S et al (2016) Automated quantitative computed tomography versus visual computed tomography scoring in idiopathic pulmonary fibrosis: validation against pulmonary function. J Thorac Imaging 31:304–311PubMed
39.
Zurück zum Zitat Jacob J, Bartholmai BJ, Rajagopalan S et al (2018) Serial automated quantitative CT analysis in idiopathic pulmonary fibrosis: functional correlations and comparison with changes in visual CT scores. Eur Radiol 28:1318–1327PubMed Jacob J, Bartholmai BJ, Rajagopalan S et al (2018) Serial automated quantitative CT analysis in idiopathic pulmonary fibrosis: functional correlations and comparison with changes in visual CT scores. Eur Radiol 28:1318–1327PubMed
40.
Zurück zum Zitat Jacob J, Bartholmai BJ, Van Moorsel CH et al (2018) Longitudinal prediction of outcome in idiopathic pulmonary fibrosis using automated CT analysis. Am J Respir Crit Care Med 197:A5926 Jacob J, Bartholmai BJ, Van Moorsel CH et al (2018) Longitudinal prediction of outcome in idiopathic pulmonary fibrosis using automated CT analysis. Am J Respir Crit Care Med 197:A5926
41.
Zurück zum Zitat Maldonado F, Moua T, Rajagopalan S et al (2014) Automated quantification of radiological patterns predicts survival in idiopathic pulmonary fibrosis. Eur Respir J 43:204–212PubMed Maldonado F, Moua T, Rajagopalan S et al (2014) Automated quantification of radiological patterns predicts survival in idiopathic pulmonary fibrosis. Eur Respir J 43:204–212PubMed
42.
Zurück zum Zitat Crews MS, Bartholmai BJ, Adegunsoye A et al (2020) Automated CT analysis of major forms of interstitial lung disease. J Clin Med 9(11):3776PubMedPubMedCentral Crews MS, Bartholmai BJ, Adegunsoye A et al (2020) Automated CT analysis of major forms of interstitial lung disease. J Clin Med 9(11):3776PubMedPubMedCentral
43.
Zurück zum Zitat Jacob J, Bartholmai BJ, Rajagopalan S et al (2017) Mortality prediction in idiopathic pulmonary fibrosis: evaluation of computer-based CT analysis with conventional severity measures. Eur Respir J 49(1):1601011 Jacob J, Bartholmai BJ, Rajagopalan S et al (2017) Mortality prediction in idiopathic pulmonary fibrosis: evaluation of computer-based CT analysis with conventional severity measures. Eur Respir J 49(1):1601011
44.
Zurück zum Zitat Mogulkoc N, Brutsche MH, Bishop PW et al (2001) Pulmonary function in idiopathic pulmonary fibrosis and referral for lung transplantation. Am J Respir Crit Care Med 164:103–108PubMed Mogulkoc N, Brutsche MH, Bishop PW et al (2001) Pulmonary function in idiopathic pulmonary fibrosis and referral for lung transplantation. Am J Respir Crit Care Med 164:103–108PubMed
45.
Zurück zum Zitat Li X, Peng S, Wei L, Li Z (2014) Relevance analysis of clinical and lung function parameters changing and prognosis of idiopathic pulmonary fibrosis. Int J Clin Exp Med 7:4759–4769PubMedPubMedCentral Li X, Peng S, Wei L, Li Z (2014) Relevance analysis of clinical and lung function parameters changing and prognosis of idiopathic pulmonary fibrosis. Int J Clin Exp Med 7:4759–4769PubMedPubMedCentral
46.
Zurück zum Zitat Latsi PI, du Bois RM, Nicholson AG et al (2003) Fibrotic idiopathic interstitial pneumonia: the prognostic value of longitudinal functional trends. Am J Respir Crit Care Med 168:531–537PubMed Latsi PI, du Bois RM, Nicholson AG et al (2003) Fibrotic idiopathic interstitial pneumonia: the prognostic value of longitudinal functional trends. Am J Respir Crit Care Med 168:531–537PubMed
47.
Zurück zum Zitat Collard HR, King TE Jr, Bartelson BB, Vourlekis JS, Schwarz MI, Brown KK (2003) Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 168:538–542PubMed Collard HR, King TE Jr, Bartelson BB, Vourlekis JS, Schwarz MI, Brown KK (2003) Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 168:538–542PubMed
48.
Zurück zum Zitat Ley B, Ryerson CJ, Vittinghoff E et al (2012) A multidimensional index and staging system for idiopathic pulmonary fibrosis. Ann Intern Med 156:684–U658PubMed Ley B, Ryerson CJ, Vittinghoff E et al (2012) A multidimensional index and staging system for idiopathic pulmonary fibrosis. Ann Intern Med 156:684–U658PubMed
49.
Zurück zum Zitat Fisher M, Nathan SD, Hill C et al (2017) Predicting life expectancy for pirfenidone in idiopathic pulmonary fibrosis. J Manag Care Spec Pharm 23:S17–s24PubMed Fisher M, Nathan SD, Hill C et al (2017) Predicting life expectancy for pirfenidone in idiopathic pulmonary fibrosis. J Manag Care Spec Pharm 23:S17–s24PubMed
50.
Zurück zum Zitat Procter AJ, Jacob J (2019) Visual vs. computer-based computed tomography analysis for the identification of functional patterns in interstitial lung diseases. Curr Opin Pulm Med 25:426–433PubMed Procter AJ, Jacob J (2019) Visual vs. computer-based computed tomography analysis for the identification of functional patterns in interstitial lung diseases. Curr Opin Pulm Med 25:426–433PubMed
51.
Zurück zum Zitat Salisbury ML, Xia M, Zhou Y et al (2016) Idiopathic pulmonary fibrosis: Gender-Age-Physiology index stage for predicting future lung function decline. Chest 149:491–498PubMedPubMedCentral Salisbury ML, Xia M, Zhou Y et al (2016) Idiopathic pulmonary fibrosis: Gender-Age-Physiology index stage for predicting future lung function decline. Chest 149:491–498PubMedPubMedCentral
52.
Zurück zum Zitat Lynch DA, Sverzellati N, Travis WD et al (2018) Diagnostic criteria for idiopathic pulmonary fibrosis: a Fleischner Society White Paper. Lancet Respir Med 6:138–153PubMed Lynch DA, Sverzellati N, Travis WD et al (2018) Diagnostic criteria for idiopathic pulmonary fibrosis: a Fleischner Society White Paper. Lancet Respir Med 6:138–153PubMed
Metadaten
Titel
The effect of CALIPER-derived parameters for idiopathic pulmonary fibrosis in predicting prognosis, progression, and mortality: a systematic review
verfasst von
Xin-yao Jiao
Han Song
Wei-wu Liu
Jun-ling Yang
Zhi-wei Wang
Dan Yang
Sa Huang
Publikationsdatum
01.08.2023
Verlag
Springer Berlin Heidelberg
Erschienen in
European Radiology / Ausgabe 10/2023
Print ISSN: 0938-7994
Elektronische ISSN: 1432-1084
DOI
https://doi.org/10.1007/s00330-023-10010-w

Weitere Artikel der Ausgabe 10/2023

European Radiology 10/2023 Zur Ausgabe

Mammakarzinom: Brustdichte beeinflusst rezidivfreies Überleben

26.05.2024 Mammakarzinom Nachrichten

Frauen, die zum Zeitpunkt der Brustkrebsdiagnose eine hohe mammografische Brustdichte aufweisen, haben ein erhöhtes Risiko für ein baldiges Rezidiv, legen neue Daten nahe.

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

17.05.2024 Klinik aktuell Nachrichten

Sie sei „ethisch geboten“, meint Gesundheitsminister Karl Lauterbach: mehr Transparenz über die Qualität von Klinikbehandlungen. Um sie abzubilden, lässt er gegen den Widerstand vieler Länder einen virtuellen Klinik-Atlas freischalten.

Klinikreform soll zehntausende Menschenleben retten

15.05.2024 Klinik aktuell Nachrichten

Gesundheitsminister Lauterbach hat die vom Bundeskabinett beschlossene Klinikreform verteidigt. Kritik an den Plänen kommt vom Marburger Bund. Und in den Ländern wird über den Gang zum Vermittlungsausschuss spekuliert.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.